Nymox Pharmaceutical Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Averback DABP,
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Bay & Deveaux Streets Nassau Bahamas
- IPO Date
- Nov 26, 1997
- CIK
- 0001018735
- Website
- nymox.com
- Similar Companies
- Business
- Nymox Pharmaceutical Corporation (Nasdaq: NYMX) develops biopharmaceutical therapeutics and diagnostics targeting unmet needs of the aging male population, with a primary focus on urological disorders including benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The company's lead product candidate, Fexapotide Triflutate (also known as NX1207 or NYMOZARFEX), a novel injectable therapy administered directly into the prostate, has completed Phase 3 clinical trials involving over 1,700 patients across more than 70 U.S. centers and a Phase 2 trial demonstrating long-term benefits such as delayed disease progression up to five years; it also advances programs for early-stage prostate cancer and holds U.S. and global patents for statin use in Alzheimer's disease treatment and prevention. Nymox markets diagnostic products NicAlert, a test strip for smoking status using saliva or urine samples cleared by U.S. FDA 510(k) and bearing CE Mark for Europe, and TobacAlert, a home test measuring tobacco product exposure including secondhand smoke; these products serve research, medical, and consumer markets globally. Founded in 1989 and headquartered in Nassau, Bahamas, with offices in Canada, the United States, and Switzerland, Nymox operates in the biotechnology sector across North America and Europe, serving healthcare providers, researchers, and patients in developed economies amid rapidly aging demographics. The company maintains a lean structure with approximately 16 employees and trades publicly on Nasdaq. Recent developments include the March 2025 dismissal of a Delaware legal action against AscellaHealth, following disputes over a previously proposed partnership that offered $12 million in non-recourse cash funding and treasury share purchases; Nymox pursues regulatory filings for Fexapotide Triflutate approval in major markets including the United States and Europe, with a Marketing Authorization Application under review in Denmark since early 2023 and additional submissions planned. In August 2023, Nymox completed a $2 million private placement for working capital, building on a prior $6.4 million financing in 2022; it also secured a Nasdaq listing compliance extension into mid-2023 and appointed Christopher R. Riley as CFO to bolster financial strategy. Ongoing efforts encompass headquarters relocation from the Bahamas to Switzerland and progression of pipeline candidates addressing large urology markets.
The Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special Meeting
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
Nymox Reports on U.S. Patent Issuances
Nymox Update
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
NYMOX Update
Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?
Why Nymox Pharma Shares Sinking to 52-Week Low?
NYMOX Provides Current Update
NYMOX Provides Shareholder Update
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
Nymox Provides New Update on Regulatory Activities
Nymox Provides Update on Regulatory Filing Activities
The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO